Advances in oral drug administration are the focus of a new agreement between the A&M System and Peroral Biosciences, Inc.
Texas A&M Innovation completed an exclusive license agreement with Peroral Biosciences, Inc., an early-stage biotech startup based in San Diego, CA, for two technologies related to oral delivery of drugs. The technologies were invented by a team from Texas A&M Health’s School of Pharmacy, led by Dr. M.N.V. Ravi Kumar with contributors Dr. Prabhjot Saini, Dr. Raghu Ganugula, and Dr. Meenakshi Arora.
Many challenges exist with conventional methods of oral drug administration including poor solubility and absorption in the GI tract. These Texas A&M technologies (U.S. Patent No. 10,786,465 and U.S. Patent No. 10,780,175) use multifunctional nanosystems to facilitate the oral delivery of certain bioactives and drugs that were previously not possible. The invention enables customized delivery of drugs with minimal effects to non-targeted areas.
“We are excited about licensing the novel oral delivery nanosystem technology from Texas A&M invented by Professor Kumar,” commented Dr. Prasad Sunkara, President of Peroral Biosciences. Dr. Sunkara explained that with the technologies now licensed from The Texas A&M University System, Peroral plans to develop them into an innovative platform for oral drug delivery. The company has raised seed funding to expand the utility of the technology and expects some of the products to move to clinical trials in 2-3 years.
Texas A&M Innovation at College Station works with a diverse array of partners – including entrepreneurs, investors, technology incubators, and large enterprises – to improve lives by commercializing innovations from The Texas A&M University System. Texas A&M research generates more than 300 new technologies each year, providing abundant and varied opportunities for industry collaboration. Learn more about the Texas A&M Innovation technology portfolio.
